Search Results For:
- Key Term:
- WHO Prequalification (WHO PQ)
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
Atreca - Gates Medical Research Institute, Malaria Monoclonal Antibodies License Agreement
2021
Industry
Non-profit research organization
Non-profit research organization
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
2023
Funder
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Field Testing
Commercialization
Field Testing
CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
2021
Funder
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Early clinical (through Phase 2)
Ferring - MPP, Post-Partum Hemorrhage Prevention & Treatment (Heat Stable Carbetocin) MOU
2023
Industry
Multilateral organization
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
FIND Sample Funding Terms and Conditions
2021
Academic institution
Industry
Product development partnership
Industry
Product development partnership
Diagnostic
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
GARDP – Orchid Pharma Ltd., Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
2023
Industry
Product development partnership
Product development partnership
Drug
Commercialization
Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
2015
Funder
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable access | Ensuring continuity
- Equitable access | Access plans & principles
- Equitable access | Affordable pricing
- Equitable access | Territory access commitments
- Business model | Governance
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Term & termination | Effects of termination
- Term & termination | Term of agreement
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
Gilead, HIV Therapeutic (Lenacapavir) Template License Agreement
2024
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
MedinCell - MPP, Malaria Vector Control (mdc-STM/ivermectin formulation) License Agreement
2022
Industry
Multilateral organization
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
AbbVie – MPP, HIV Antiretroviral (lopinavir, ritonavir - LPV/r) License Agreement
2016
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
AbbVie - MPP, HIV Antiretroviral (lopinavir, ritonavir - LPV/r) Pediatric License Agreement
2014
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
2024
Industry
Multilateral organization
Multilateral organization
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
BMS - MPP, Hepatitis C Antiviral (daclatasvir - DAC) License & Tech Transfer Agreement
2016
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
BMS - MPP, HIV Antiretroviral (atazanavir - ATV) License and Technology Transfer Agreement
2017
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
2023
Industry
Multilateral organization
Multilateral organization
Vaccine
Commercialization
MPP - Gates Medical Research Institute, TB therapeutic (Sutezolid) Sublicense Agreement
2020
Industry
Multilateral organization
Non-profit research organization
Multilateral organization
Non-profit research organization
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
Gilead - MPP - Arene Lifesciences, HIV Therapeutic License Agreement
2018
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
Pfizer - MPP, TB Therapeutic (Sutezolid) Non-Exclusive License Agreement
2019
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
University of Liverpool – MPP, HIV Therapeutic Collaboration Agreement and Patent & Know-How License
2015
Academic institution
Multilateral organization
Multilateral organization
Drug
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Merck - MPP, Molnupiravir License Agreement
2021
Industry
Multilateral organization
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
Novartis – MPP, Nilotinib, Non-Exclusive License Agreement
2022
Industry
Multilateral organization
Multilateral organization
Drug
Commercialization
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Industry
Vaccine
Commercialization
Shionogi - GARDP, Cefiderocol License Agreement
2022
Industry
Product development partnership
Product development partnership
Drug
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
University of Washington - MPP, Long-acting Injectable HIV Treatment License Agreement
2021
Academic institution
Multilateral organization
Multilateral organization
Drug
Preclinical
Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
2024
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
ViiV - MPP, HIV Prevention Medicine (Cabotegravir LA for PrEP), License Agreement
2022
Industry
Multilateral organization
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
GHIAA2019\MapguideSearch Object
(
[search_parameters] => Array
(
[key_term] => who-prequalification
)
[filters] => Array
(
[provision] => Array
(
[key_term] => who-prequalification
)
)
[child_filters] => Array
(
)
[agreement_args] =>
[provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => key_term
[field] => slug
[terms] => who-prequalification
)
)
)
[text_agreement_args] =>
[text_provision_args] =>
[agreement_ids] => Array
(
)
[agreement_q_rslts] =>
[provision_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => key_term
[field] => slug
[terms] => who-prequalification
)
)
)
[query_vars] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[tax_query] => Array
(
[0] => Array
(
[taxonomy] => key_term
[field] => slug
[terms] => who-prequalification
)
)
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[s] =>
[sentence] =>
[title] =>
[fields] => all
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[search_columns] => Array
(
)
[ignore_sticky_posts] =>
[suppress_filters] =>
[cache_results] => 1
[update_post_term_cache] => 1
[update_menu_item_cache] =>
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[taxonomy] => key_term
[term] => who-prequalification
[order] => DESC
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
[0] => Array
(
[taxonomy] => key_term
[terms] => Array
(
[0] => who-prequalification
)
[field] => slug
[operator] => IN
[include_children] => 1
)
)
[relation] => AND
[table_aliases:protected] => Array
(
[0] => wpry_term_relationships
)
[queried_terms] => Array
(
[key_term] => Array
(
[terms] => Array
(
[0] => who-prequalification
)
[field] => slug
)
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] => SELECT wpry_posts.*
FROM wpry_posts LEFT JOIN wpry_term_relationships ON (wpry_posts.ID = wpry_term_relationships.object_id)
WHERE 1=1 AND (
wpry_term_relationships.term_taxonomy_id IN (324)
) AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
GROUP BY wpry_posts.ID
ORDER BY wpry_posts.post_date DESC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 13136
[post_author] => 5
[post_date] => 2025-10-23 11:26:18
[post_date_gmt] => 2025-10-23 11:26:18
[post_content] =>
[post_title] => Ferring - MPP, Post-Partum Hemorrhage Prevention & Treatment (Heat Stable Carbetocin) MOU
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ferring-mpp-post-partum-hemorrhage-prevention-treatment-heat-stable-carbetocin-mou-12
[to_ping] =>
[pinged] =>
[post_modified] => 2025-10-23 12:00:48
[post_modified_gmt] => 2025-10-23 12:00:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=13136
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 13135
[post_author] => 5
[post_date] => 2025-10-23 11:26:12
[post_date_gmt] => 2025-10-23 11:26:12
[post_content] =>
[post_title] => Ferring - MPP, Post-Partum Hemorrhage Prevention & Treatment (Heat Stable Carbetocin) MOU
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ferring-mpp-post-partum-hemorrhage-prevention-treatment-heat-stable-carbetocin-mou-11
[to_ping] =>
[pinged] =>
[post_modified] => 2025-10-23 12:02:11
[post_modified_gmt] => 2025-10-23 12:02:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=13135
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 13132
[post_author] => 5
[post_date] => 2025-10-23 11:25:48
[post_date_gmt] => 2025-10-23 11:25:48
[post_content] =>
[post_title] => Ferring - MPP, Post-Partum Hemorrhage Prevention & Treatment (Heat Stable Carbetocin) MOU
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ferring-mpp-post-partum-hemorrhage-prevention-treatment-heat-stable-carbetocin-mou-8
[to_ping] =>
[pinged] =>
[post_modified] => 2025-10-23 12:20:01
[post_modified_gmt] => 2025-10-23 12:20:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=13132
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 13126
[post_author] => 5
[post_date] => 2025-10-23 11:25:26
[post_date_gmt] => 2025-10-23 11:25:26
[post_content] =>
[post_title] => Ferring - MPP, Post-Partum Hemorrhage Prevention & Treatment (Heat Stable Carbetocin) MOU
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ferring-mpp-post-partum-hemorrhage-prevention-treatment-heat-stable-carbetocin-mou-5
[to_ping] =>
[pinged] =>
[post_modified] => 2025-10-23 11:25:26
[post_modified_gmt] => 2025-10-23 11:25:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=13126
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 13141
[post_author] => 5
[post_date] => 2025-10-06 08:25:12
[post_date_gmt] => 2025-10-06 08:25:12
[post_content] =>
[post_title] => Ferring - MPP, Post-Partum Hemorrhage Prevention & Treatment (Heat Stable Carbetocin) MOU
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ferring-mpp-post-partum-hemorrhage-prevention-treatment-heat-stable-carbetocin-mou-2
[to_ping] =>
[pinged] =>
[post_modified] => 2025-10-23 12:32:49
[post_modified_gmt] => 2025-10-23 12:32:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=13141
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 12964
[post_author] => 5
[post_date] => 2025-08-13 12:25:57
[post_date_gmt] => 2025-08-13 12:25:57
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-13
[to_ping] =>
[pinged] =>
[post_modified] => 2025-08-13 12:30:46
[post_modified_gmt] => 2025-08-13 12:30:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12964
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 12947
[post_author] => 5
[post_date] => 2025-08-07 09:49:53
[post_date_gmt] => 2025-08-07 09:49:53
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-3
[to_ping] =>
[pinged] =>
[post_modified] => 2025-08-20 08:48:35
[post_modified_gmt] => 2025-08-20 08:48:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12947
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 12765
[post_author] => 5
[post_date] => 2025-07-23 13:21:13
[post_date_gmt] => 2025-07-23 13:21:13
[post_content] =>
[post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-18
[to_ping] =>
[pinged] =>
[post_modified] => 2025-07-23 13:21:13
[post_modified_gmt] => 2025-07-23 13:21:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12765
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 12800
[post_author] => 5
[post_date] => 2025-06-26 07:30:41
[post_date_gmt] => 2025-06-26 07:30:41
[post_content] =>
[post_title] => Atreca - Gates Medical Research Institute, Malaria Monoclonal Antibodies License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => atreca-gates-medical-research-institute-malaria-monoclonal-antibodies-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-26 08:54:06
[post_modified_gmt] => 2025-06-26 08:54:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 12780
[post_author] => 5
[post_date] => 2025-06-18 11:05:07
[post_date_gmt] => 2025-06-18 11:05:07
[post_content] =>
[post_title] => MedinCell - MPP, Malaria Vector Control (mdc-STM/ivermectin formulation) License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => medincell-mpp-malaria-vector-control-mdc-stm-ivermectin-formulation-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-18 11:38:09
[post_modified_gmt] => 2025-06-18 11:38:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12780
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 12782
[post_author] => 5
[post_date] => 2025-06-18 11:04:56
[post_date_gmt] => 2025-06-18 11:04:56
[post_content] =>
[post_title] => MedinCell - MPP, Malaria Vector Control (mdc-STM/ivermectin formulation) License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => medincell-mpp-malaria-vector-control-mdc-stm-ivermectin-formulation-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-18 12:02:46
[post_modified_gmt] => 2025-06-18 12:02:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12782
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 12790
[post_author] => 5
[post_date] => 2025-06-18 11:04:01
[post_date_gmt] => 2025-06-18 11:04:01
[post_content] =>
[post_title] => MedinCell - MPP, Malaria Vector Control (mdc-STM/ivermectin formulation) License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => medincell-mpp-malaria-vector-control-mdc-stm-ivermectin-formulation-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-18 11:35:35
[post_modified_gmt] => 2025-06-18 11:35:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12790
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 12764
[post_author] => 5
[post_date] => 2025-06-13 14:15:31
[post_date_gmt] => 2025-06-13 14:15:31
[post_content] =>
[post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-13 14:15:31
[post_modified_gmt] => 2025-06-13 14:15:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12764
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 12759
[post_author] => 5
[post_date] => 2025-06-13 14:15:03
[post_date_gmt] => 2025-06-13 14:15:03
[post_content] =>
[post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-13 14:31:52
[post_modified_gmt] => 2025-06-13 14:31:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12759
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 12758
[post_author] => 5
[post_date] => 2025-06-13 14:14:57
[post_date_gmt] => 2025-06-13 14:14:57
[post_content] =>
[post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-13 14:14:57
[post_modified_gmt] => 2025-06-13 14:14:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12758
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 12756
[post_author] => 5
[post_date] => 2025-06-13 14:14:36
[post_date_gmt] => 2025-06-13 14:14:36
[post_content] =>
[post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-13 14:40:06
[post_modified_gmt] => 2025-06-13 14:40:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12756
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 12709
[post_author] => 5
[post_date] => 2025-05-22 09:09:31
[post_date_gmt] => 2025-05-22 09:09:31
[post_content] =>
[post_title] => ViiV - MPP, HIV Prevention Medicine (Cabotegravir LA for PrEP), License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => viiv-mpp-hiv-prevention-medicine-cabotegravir-la-for-prep-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2025-05-22 10:07:26
[post_modified_gmt] => 2025-05-22 10:07:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12709
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 12716
[post_author] => 5
[post_date] => 2025-05-22 08:56:21
[post_date_gmt] => 2025-05-22 08:56:21
[post_content] =>
[post_title] => ViiV - MPP, HIV Prevention Medicine (Cabotegravir LA for PrEP), License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => viiv-mpp-hiv-prevention-medicine-cabotegravir-la-for-prep-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2025-05-22 09:57:25
[post_modified_gmt] => 2025-05-22 09:57:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12716
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 12723
[post_author] => 5
[post_date] => 2025-05-22 08:55:23
[post_date_gmt] => 2025-05-22 08:55:23
[post_content] =>
[post_title] => ViiV - MPP, HIV Prevention Medicine (Cabotegravir LA for PrEP), License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => viiv-mpp-hiv-prevention-medicine-cabotegravir-la-for-prep-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2025-05-22 09:44:44
[post_modified_gmt] => 2025-05-22 09:44:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12723
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 12724
[post_author] => 5
[post_date] => 2025-05-22 08:55:16
[post_date_gmt] => 2025-05-22 08:55:16
[post_content] =>
[post_title] => ViiV - MPP, HIV Prevention Medicine (Cabotegravir LA for PrEP), License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => viiv-mpp-hiv-prevention-medicine-cabotegravir-la-for-prep-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2025-05-22 09:37:40
[post_modified_gmt] => 2025-05-22 09:37:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12724
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 12468
[post_author] => 5
[post_date] => 2025-01-07 13:44:33
[post_date_gmt] => 2025-01-07 13:44:33
[post_content] =>
[post_title] => University of Liverpool – MPP, HIV Therapeutic Collaboration Agreement and Patent & Know-How License
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-liverpool-mpp-hiv-therapeutic-collaboration-agreement-and-patent-know-how-license-4
[to_ping] =>
[pinged] =>
[post_modified] => 2025-01-07 13:44:33
[post_modified_gmt] => 2025-01-07 13:44:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12468
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 12145
[post_author] => 5
[post_date] => 2024-10-23 12:16:31
[post_date_gmt] => 2024-10-23 12:16:31
[post_content] =>
[post_title] => Gilead, HIV Therapeutic (Lenacapavir) Template License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hiv-therapeutic-lenacapavir-template-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-23 13:02:53
[post_modified_gmt] => 2024-10-23 13:02:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12145
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 12216
[post_author] => 5
[post_date] => 2024-10-23 12:15:49
[post_date_gmt] => 2024-10-23 12:15:49
[post_content] =>
[post_title] => Gilead, HIV Therapeutic (Lenacapavir) Template License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hiv-therapeutic-lenacapavir-template-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-23 12:43:46
[post_modified_gmt] => 2024-10-23 12:43:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 12220
[post_author] => 5
[post_date] => 2024-10-23 12:15:23
[post_date_gmt] => 2024-10-23 12:15:23
[post_content] =>
[post_title] => Gilead, HIV Therapeutic (Lenacapavir) Template License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hiv-therapeutic-lenacapavir-template-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-23 13:10:50
[post_modified_gmt] => 2024-10-23 13:10:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 12016
[post_author] => 5
[post_date] => 2024-10-17 09:08:34
[post_date_gmt] => 2024-10-17 09:08:34
[post_content] =>
[post_title] => Novartis – MPP, Nilotinib, Non-Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novartis-mpp-nilotinib-non-exclusive-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2025-10-15 11:11:41
[post_modified_gmt] => 2025-10-15 11:11:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12016
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 12117
[post_author] => 5
[post_date] => 2024-10-17 09:08:28
[post_date_gmt] => 2024-10-17 09:08:28
[post_content] =>
[post_title] => Novartis – MPP, Nilotinib, Non-Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novartis-mpp-nilotinib-non-exclusive-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-17 09:08:28
[post_modified_gmt] => 2024-10-17 09:08:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12117
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 12126
[post_author] => 5
[post_date] => 2024-10-17 09:05:38
[post_date_gmt] => 2024-10-17 09:05:38
[post_content] =>
[post_title] => Novartis – MPP, Nilotinib, Non-Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novartis-mpp-nilotinib-non-exclusive-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-17 10:04:30
[post_modified_gmt] => 2024-10-17 10:04:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12126
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 12097
[post_author] => 5
[post_date] => 2024-10-09 14:59:36
[post_date_gmt] => 2024-10-09 14:59:36
[post_content] =>
[post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-09 14:59:36
[post_modified_gmt] => 2024-10-09 14:59:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12097
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 12040
[post_author] => 5
[post_date] => 2024-09-06 15:04:16
[post_date_gmt] => 2024-09-06 15:04:16
[post_content] =>
[post_title] => AbbVie – MPP, HIV Antiretroviral (lopinavir, ritonavir – LPV/r) Pediatric License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => abbvie-mpp-hiv-antiretroviral-lopinavir-ritonavir-lpv-r-pediatric-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-05 15:11:50
[post_modified_gmt] => 2024-11-05 15:11:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12040
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 12031
[post_author] => 5
[post_date] => 2024-09-05 10:50:42
[post_date_gmt] => 2024-09-05 10:50:42
[post_content] =>
[post_title] => BMS - MPP, Hepatitis C Antiviral (daclatasvir - DAC) License & Tech Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bms-mpp-hepatitis-c-antiviral-daclatasvir-dac-license-tech-transfer-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-05 12:58:28
[post_modified_gmt] => 2024-09-05 12:58:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12031
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 12026
[post_author] => 5
[post_date] => 2024-09-04 15:25:56
[post_date_gmt] => 2024-09-04 15:25:56
[post_content] =>
[post_title] => AbbVie – MPP, HIV Antiretroviral (lopinavir, ritonavir – LPV/r) Pediatric License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => abbvie-mpp-hiv-antiretroviral-lopinavir-ritonavir-lpv-r-pediatric-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-05 14:52:17
[post_modified_gmt] => 2024-11-05 14:52:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12026
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 12023
[post_author] => 5
[post_date] => 2024-09-04 13:09:05
[post_date_gmt] => 2024-09-04 13:09:05
[post_content] =>
[post_title] => AbbVie – MPP, HIV Antiretroviral (lopinavir, ritonavir - LPV/r) License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => abbvie-mpp-hiv-antiretroviral-lopinavir-ritonavir-lpv-r-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 13:09:05
[post_modified_gmt] => 2024-09-04 13:09:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12023
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 11816
[post_author] => 5
[post_date] => 2024-09-04 10:53:36
[post_date_gmt] => 2024-09-04 10:53:36
[post_content] =>
[post_title] => Pfizer - MPP, TB Therapeutic (Sutezolid) Non-Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-mpp-tb-therapeutic-sutezolid-non-exclusive-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:53:36
[post_modified_gmt] => 2024-09-04 10:53:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11816
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 11817
[post_author] => 5
[post_date] => 2024-09-04 10:53:13
[post_date_gmt] => 2024-09-04 10:53:13
[post_content] =>
[post_title] => MPP - Gates Medical Research Institute, TB therapeutic (Sutezolid) Sublicense Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-gates-medical-research-institute-tb-therapeutic-sutezolid-sublicense-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:53:13
[post_modified_gmt] => 2024-09-04 10:53:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11817
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 12019
[post_author] => 5
[post_date] => 2024-09-04 10:27:15
[post_date_gmt] => 2024-09-04 10:27:15
[post_content] =>
[post_title] => BMS - MPP, HIV Antiretroviral (atazanavir - ATV) License and Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bms-mpp-sublicense-tech-transfer-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-05 13:02:57
[post_modified_gmt] => 2024-09-05 13:02:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12019
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 11809
[post_author] => 5
[post_date] => 2024-05-30 14:34:08
[post_date_gmt] => 2024-05-30 14:34:08
[post_content] =>
[post_title] => Pfizer - MPP, TB Therapeutic (Sutezolid) Non-Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-mpp-tb-therapeutic-sutezolid-non-exclusive-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2024-05-31 07:05:35
[post_modified_gmt] => 2024-05-31 07:05:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11809
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 11794
[post_author] => 5
[post_date] => 2024-05-30 09:59:21
[post_date_gmt] => 2024-05-30 09:59:21
[post_content] =>
[post_title] => MPP – Gates Medical Research Institute, TB therapeutic (Sutezolid) Sublicense Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-gates-medical-research-institute-tb-therapeutic-sutezolid-sublicense-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-05-30 11:13:31
[post_modified_gmt] => 2024-05-30 11:13:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11794
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 11480
[post_author] => 5
[post_date] => 2023-11-20 09:24:22
[post_date_gmt] => 2023-11-20 09:24:22
[post_content] =>
[post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:51:14
[post_modified_gmt] => 2024-09-04 10:51:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11480
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 11471
[post_author] => 5
[post_date] => 2023-11-20 08:40:37
[post_date_gmt] => 2023-11-20 08:40:37
[post_content] =>
[post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-28 12:47:50
[post_modified_gmt] => 2024-10-28 12:47:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11471
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 11468
[post_author] => 5
[post_date] => 2023-11-20 08:37:54
[post_date_gmt] => 2023-11-20 08:37:54
[post_content] =>
[post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-11-20 09:25:50
[post_modified_gmt] => 2023-11-20 09:25:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11468
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 11356
[post_author] => 5
[post_date] => 2023-10-11 13:32:54
[post_date_gmt] => 2023-10-11 13:32:54
[post_content] =>
[post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:51:51
[post_modified_gmt] => 2024-09-04 10:51:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11356
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 3910
[post_author] => 5
[post_date] => 2022-12-15 14:44:16
[post_date_gmt] => 2022-12-15 14:44:16
[post_content] =>
[post_title] => Merck – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:52:12
[post_modified_gmt] => 2024-09-04 10:52:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3910
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 8131
[post_author] => 5
[post_date] => 2022-12-12 09:57:36
[post_date_gmt] => 2022-12-12 09:57:36
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-18 15:13:14
[post_modified_gmt] => 2024-11-18 15:13:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 8130
[post_author] => 5
[post_date] => 2022-12-12 09:34:49
[post_date_gmt] => 2022-12-12 09:34:49
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-18 15:13:39
[post_modified_gmt] => 2024-11-18 15:13:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8130
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 8051
[post_author] => 5
[post_date] => 2022-12-12 08:39:19
[post_date_gmt] => 2022-12-12 08:39:19
[post_content] =>
[post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-18 15:14:21
[post_modified_gmt] => 2024-11-18 15:14:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8051
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 7580
[post_author] => 5
[post_date] => 2022-12-08 08:14:21
[post_date_gmt] => 2022-12-08 08:14:21
[post_content] =>
[post_title] => FIND Sample Funding Terms and Conditions
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => find-sample-funding-terms-and-conditions-7
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:50:41
[post_modified_gmt] => 2024-09-04 10:50:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=7580
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 6636
[post_author] => 5
[post_date] => 2022-11-09 13:21:22
[post_date_gmt] => 2022-11-09 13:21:22
[post_content] =>
[post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-11 09:35:07
[post_modified_gmt] => 2023-07-11 09:35:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6636
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 6635
[post_author] => 5
[post_date] => 2022-11-09 13:05:41
[post_date_gmt] => 2022-11-09 13:05:41
[post_content] =>
[post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-19 15:11:40
[post_modified_gmt] => 2024-08-19 15:11:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6635
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 6634
[post_author] => 5
[post_date] => 2022-11-08 19:23:52
[post_date_gmt] => 2022-11-08 19:23:52
[post_content] =>
[post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-11 09:43:33
[post_modified_gmt] => 2023-07-11 09:43:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6634
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 6632
[post_author] => 5
[post_date] => 2022-11-08 18:14:54
[post_date_gmt] => 2022-11-08 18:14:54
[post_content] =>
[post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-11 08:47:59
[post_modified_gmt] => 2023-07-11 08:47:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6632
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[50] => WP_Post Object
(
[ID] => 6631
[post_author] => 5
[post_date] => 2022-11-08 16:07:28
[post_date_gmt] => 2022-11-08 16:07:28
[post_content] =>
[post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2025-08-20 08:59:54
[post_modified_gmt] => 2025-08-20 08:59:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6631
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[51] => WP_Post Object
(
[ID] => 6630
[post_author] => 5
[post_date] => 2022-11-08 15:22:11
[post_date_gmt] => 2022-11-08 15:22:11
[post_content] =>
[post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-11 08:56:26
[post_modified_gmt] => 2023-07-11 08:56:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6630
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[52] => WP_Post Object
(
[ID] => 6628
[post_author] => 5
[post_date] => 2022-11-08 13:12:06
[post_date_gmt] => 2022-11-08 13:12:06
[post_content] =>
[post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-19 15:13:38
[post_modified_gmt] => 2024-08-19 15:13:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6628
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[53] => WP_Post Object
(
[ID] => 5800
[post_author] => 5
[post_date] => 2022-09-28 07:45:10
[post_date_gmt] => 2022-09-28 07:45:10
[post_content] =>
[post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-19 14:46:23
[post_modified_gmt] => 2024-09-19 14:46:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[54] => WP_Post Object
(
[ID] => 5281
[post_author] => 5
[post_date] => 2022-07-08 12:00:54
[post_date_gmt] => 2022-07-08 12:00:54
[post_content] =>
[post_title] => Shionogi – GARDP, Cefiderocol License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => shionogi-gardp-cefiderocol-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:54:17
[post_modified_gmt] => 2024-09-04 10:54:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5281
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[55] => WP_Post Object
(
[ID] => 5278
[post_author] => 5
[post_date] => 2022-07-08 10:25:20
[post_date_gmt] => 2022-07-08 10:25:20
[post_content] =>
[post_title] => Shionogi – GARDP, Cefiderocol License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => shionogi-gardp-cefiderocol-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-18 11:50:51
[post_modified_gmt] => 2023-07-18 11:50:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5278
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[56] => WP_Post Object
(
[ID] => 5270
[post_author] => 5
[post_date] => 2022-07-08 08:12:42
[post_date_gmt] => 2022-07-08 08:12:42
[post_content] =>
[post_title] => Shionogi - GARDP, Cefiderocol License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => shionogi-gardp-cefiderocol-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-09 13:26:03
[post_modified_gmt] => 2024-01-09 13:26:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5270
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[57] => WP_Post Object
(
[ID] => 4161
[post_author] => 5
[post_date] => 2022-02-02 13:48:58
[post_date_gmt] => 2022-02-02 13:48:58
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-20 13:31:52
[post_modified_gmt] => 2024-08-20 13:31:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4161
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[58] => WP_Post Object
(
[ID] => 4089
[post_author] => 5
[post_date] => 2022-01-11 13:35:45
[post_date_gmt] => 2022-01-11 13:35:45
[post_content] =>
[post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:55:45
[post_modified_gmt] => 2024-09-04 10:55:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4089
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[59] => WP_Post Object
(
[ID] => 4077
[post_author] => 5
[post_date] => 2022-01-11 07:20:11
[post_date_gmt] => 2022-01-11 07:20:11
[post_content] =>
[post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-11-10 15:02:23
[post_modified_gmt] => 2023-11-10 15:02:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4077
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[60] => WP_Post Object
(
[ID] => 3895
[post_author] => 5
[post_date] => 2021-11-22 10:20:20
[post_date_gmt] => 2021-11-22 10:20:20
[post_content] =>
[post_title] => Merck – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-20 08:33:01
[post_modified_gmt] => 2024-09-20 08:33:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3895
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[61] => WP_Post Object
(
[ID] => 3892
[post_author] => 5
[post_date] => 2021-11-19 13:53:26
[post_date_gmt] => 2021-11-19 13:53:26
[post_content] =>
[post_title] => Merck – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2025-09-18 14:49:01
[post_modified_gmt] => 2025-09-18 14:49:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[62] => WP_Post Object
(
[ID] => 2889
[post_author] => 6
[post_date] => 2021-05-14 19:09:07
[post_date_gmt] => 2021-05-14 19:09:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-21 11:28:56
[post_modified_gmt] => 2024-10-21 11:28:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2889
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 63
[current_post] => -1
[before_loop] => 1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 13136
[post_author] => 5
[post_date] => 2025-10-23 11:26:18
[post_date_gmt] => 2025-10-23 11:26:18
[post_content] =>
[post_title] => Ferring - MPP, Post-Partum Hemorrhage Prevention & Treatment (Heat Stable Carbetocin) MOU
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ferring-mpp-post-partum-hemorrhage-prevention-treatment-heat-stable-carbetocin-mou-12
[to_ping] =>
[pinged] =>
[post_modified] => 2025-10-23 12:00:48
[post_modified_gmt] => 2025-10-23 12:00:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=13136
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 63
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] => 1
[is_search] =>
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => 556d45d8ca46b6fe02aff99f145606ee
[query_vars_changed:WP_Query:private] =>
[thumbnails_cached] =>
[allow_query_attachment_by_filename:protected] =>
[stopwords:WP_Query:private] =>
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
[query_cache_key:WP_Query:private] => wp_query:a3a9b4cf51aadf7c3f5d1252054ae0bc
)
[text_agreement_q_rslts] =>
[text_provision_q_rslts] =>
[provisions] => Array
(
[0] => WP_Post Object
(
[ID] => 13136
[post_author] => 5
[post_date] => 2025-10-23 11:26:18
[post_date_gmt] => 2025-10-23 11:26:18
[post_content] =>
[post_title] => Ferring - MPP, Post-Partum Hemorrhage Prevention & Treatment (Heat Stable Carbetocin) MOU
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ferring-mpp-post-partum-hemorrhage-prevention-treatment-heat-stable-carbetocin-mou-12
[to_ping] =>
[pinged] =>
[post_modified] => 2025-10-23 12:00:48
[post_modified_gmt] => 2025-10-23 12:00:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=13136
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 13135
[post_author] => 5
[post_date] => 2025-10-23 11:26:12
[post_date_gmt] => 2025-10-23 11:26:12
[post_content] =>
[post_title] => Ferring - MPP, Post-Partum Hemorrhage Prevention & Treatment (Heat Stable Carbetocin) MOU
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ferring-mpp-post-partum-hemorrhage-prevention-treatment-heat-stable-carbetocin-mou-11
[to_ping] =>
[pinged] =>
[post_modified] => 2025-10-23 12:02:11
[post_modified_gmt] => 2025-10-23 12:02:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=13135
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 13132
[post_author] => 5
[post_date] => 2025-10-23 11:25:48
[post_date_gmt] => 2025-10-23 11:25:48
[post_content] =>
[post_title] => Ferring - MPP, Post-Partum Hemorrhage Prevention & Treatment (Heat Stable Carbetocin) MOU
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ferring-mpp-post-partum-hemorrhage-prevention-treatment-heat-stable-carbetocin-mou-8
[to_ping] =>
[pinged] =>
[post_modified] => 2025-10-23 12:20:01
[post_modified_gmt] => 2025-10-23 12:20:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=13132
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 13126
[post_author] => 5
[post_date] => 2025-10-23 11:25:26
[post_date_gmt] => 2025-10-23 11:25:26
[post_content] =>
[post_title] => Ferring - MPP, Post-Partum Hemorrhage Prevention & Treatment (Heat Stable Carbetocin) MOU
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ferring-mpp-post-partum-hemorrhage-prevention-treatment-heat-stable-carbetocin-mou-5
[to_ping] =>
[pinged] =>
[post_modified] => 2025-10-23 11:25:26
[post_modified_gmt] => 2025-10-23 11:25:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=13126
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 13141
[post_author] => 5
[post_date] => 2025-10-06 08:25:12
[post_date_gmt] => 2025-10-06 08:25:12
[post_content] =>
[post_title] => Ferring - MPP, Post-Partum Hemorrhage Prevention & Treatment (Heat Stable Carbetocin) MOU
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ferring-mpp-post-partum-hemorrhage-prevention-treatment-heat-stable-carbetocin-mou-2
[to_ping] =>
[pinged] =>
[post_modified] => 2025-10-23 12:32:49
[post_modified_gmt] => 2025-10-23 12:32:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=13141
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 12964
[post_author] => 5
[post_date] => 2025-08-13 12:25:57
[post_date_gmt] => 2025-08-13 12:25:57
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-13
[to_ping] =>
[pinged] =>
[post_modified] => 2025-08-13 12:30:46
[post_modified_gmt] => 2025-08-13 12:30:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12964
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 12947
[post_author] => 5
[post_date] => 2025-08-07 09:49:53
[post_date_gmt] => 2025-08-07 09:49:53
[post_content] =>
[post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement 2
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2-3
[to_ping] =>
[pinged] =>
[post_modified] => 2025-08-20 08:48:35
[post_modified_gmt] => 2025-08-20 08:48:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12947
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 12765
[post_author] => 5
[post_date] => 2025-07-23 13:21:13
[post_date_gmt] => 2025-07-23 13:21:13
[post_content] =>
[post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-18
[to_ping] =>
[pinged] =>
[post_modified] => 2025-07-23 13:21:13
[post_modified_gmt] => 2025-07-23 13:21:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12765
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 12800
[post_author] => 5
[post_date] => 2025-06-26 07:30:41
[post_date_gmt] => 2025-06-26 07:30:41
[post_content] =>
[post_title] => Atreca - Gates Medical Research Institute, Malaria Monoclonal Antibodies License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => atreca-gates-medical-research-institute-malaria-monoclonal-antibodies-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-26 08:54:06
[post_modified_gmt] => 2025-06-26 08:54:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 12780
[post_author] => 5
[post_date] => 2025-06-18 11:05:07
[post_date_gmt] => 2025-06-18 11:05:07
[post_content] =>
[post_title] => MedinCell - MPP, Malaria Vector Control (mdc-STM/ivermectin formulation) License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => medincell-mpp-malaria-vector-control-mdc-stm-ivermectin-formulation-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-18 11:38:09
[post_modified_gmt] => 2025-06-18 11:38:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12780
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 12782
[post_author] => 5
[post_date] => 2025-06-18 11:04:56
[post_date_gmt] => 2025-06-18 11:04:56
[post_content] =>
[post_title] => MedinCell - MPP, Malaria Vector Control (mdc-STM/ivermectin formulation) License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => medincell-mpp-malaria-vector-control-mdc-stm-ivermectin-formulation-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-18 12:02:46
[post_modified_gmt] => 2025-06-18 12:02:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12782
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 12790
[post_author] => 5
[post_date] => 2025-06-18 11:04:01
[post_date_gmt] => 2025-06-18 11:04:01
[post_content] =>
[post_title] => MedinCell - MPP, Malaria Vector Control (mdc-STM/ivermectin formulation) License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => medincell-mpp-malaria-vector-control-mdc-stm-ivermectin-formulation-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-18 11:35:35
[post_modified_gmt] => 2025-06-18 11:35:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12790
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 12764
[post_author] => 5
[post_date] => 2025-06-13 14:15:31
[post_date_gmt] => 2025-06-13 14:15:31
[post_content] =>
[post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-13 14:15:31
[post_modified_gmt] => 2025-06-13 14:15:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12764
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 12759
[post_author] => 5
[post_date] => 2025-06-13 14:15:03
[post_date_gmt] => 2025-06-13 14:15:03
[post_content] =>
[post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-13 14:31:52
[post_modified_gmt] => 2025-06-13 14:31:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12759
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 12758
[post_author] => 5
[post_date] => 2025-06-13 14:14:57
[post_date_gmt] => 2025-06-13 14:14:57
[post_content] =>
[post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-13 14:14:57
[post_modified_gmt] => 2025-06-13 14:14:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12758
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 12756
[post_author] => 5
[post_date] => 2025-06-13 14:14:36
[post_date_gmt] => 2025-06-13 14:14:36
[post_content] =>
[post_title] => Valneva - Serum Institute of India, Chikungunya Vaccine License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => valneva-serum-institute-of-india-chikungunya-vaccine-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2025-06-13 14:40:06
[post_modified_gmt] => 2025-06-13 14:40:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12756
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 12709
[post_author] => 5
[post_date] => 2025-05-22 09:09:31
[post_date_gmt] => 2025-05-22 09:09:31
[post_content] =>
[post_title] => ViiV - MPP, HIV Prevention Medicine (Cabotegravir LA for PrEP), License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => viiv-mpp-hiv-prevention-medicine-cabotegravir-la-for-prep-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2025-05-22 10:07:26
[post_modified_gmt] => 2025-05-22 10:07:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12709
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 12716
[post_author] => 5
[post_date] => 2025-05-22 08:56:21
[post_date_gmt] => 2025-05-22 08:56:21
[post_content] =>
[post_title] => ViiV - MPP, HIV Prevention Medicine (Cabotegravir LA for PrEP), License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => viiv-mpp-hiv-prevention-medicine-cabotegravir-la-for-prep-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2025-05-22 09:57:25
[post_modified_gmt] => 2025-05-22 09:57:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12716
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 12723
[post_author] => 5
[post_date] => 2025-05-22 08:55:23
[post_date_gmt] => 2025-05-22 08:55:23
[post_content] =>
[post_title] => ViiV - MPP, HIV Prevention Medicine (Cabotegravir LA for PrEP), License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => viiv-mpp-hiv-prevention-medicine-cabotegravir-la-for-prep-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2025-05-22 09:44:44
[post_modified_gmt] => 2025-05-22 09:44:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12723
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 12724
[post_author] => 5
[post_date] => 2025-05-22 08:55:16
[post_date_gmt] => 2025-05-22 08:55:16
[post_content] =>
[post_title] => ViiV - MPP, HIV Prevention Medicine (Cabotegravir LA for PrEP), License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => viiv-mpp-hiv-prevention-medicine-cabotegravir-la-for-prep-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2025-05-22 09:37:40
[post_modified_gmt] => 2025-05-22 09:37:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12724
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 12468
[post_author] => 5
[post_date] => 2025-01-07 13:44:33
[post_date_gmt] => 2025-01-07 13:44:33
[post_content] =>
[post_title] => University of Liverpool – MPP, HIV Therapeutic Collaboration Agreement and Patent & Know-How License
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-liverpool-mpp-hiv-therapeutic-collaboration-agreement-and-patent-know-how-license-4
[to_ping] =>
[pinged] =>
[post_modified] => 2025-01-07 13:44:33
[post_modified_gmt] => 2025-01-07 13:44:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12468
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 12145
[post_author] => 5
[post_date] => 2024-10-23 12:16:31
[post_date_gmt] => 2024-10-23 12:16:31
[post_content] =>
[post_title] => Gilead, HIV Therapeutic (Lenacapavir) Template License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hiv-therapeutic-lenacapavir-template-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-23 13:02:53
[post_modified_gmt] => 2024-10-23 13:02:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12145
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 12216
[post_author] => 5
[post_date] => 2024-10-23 12:15:49
[post_date_gmt] => 2024-10-23 12:15:49
[post_content] =>
[post_title] => Gilead, HIV Therapeutic (Lenacapavir) Template License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hiv-therapeutic-lenacapavir-template-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-23 12:43:46
[post_modified_gmt] => 2024-10-23 12:43:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 12220
[post_author] => 5
[post_date] => 2024-10-23 12:15:23
[post_date_gmt] => 2024-10-23 12:15:23
[post_content] =>
[post_title] => Gilead, HIV Therapeutic (Lenacapavir) Template License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-hiv-therapeutic-lenacapavir-template-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-23 13:10:50
[post_modified_gmt] => 2024-10-23 13:10:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 12016
[post_author] => 5
[post_date] => 2024-10-17 09:08:34
[post_date_gmt] => 2024-10-17 09:08:34
[post_content] =>
[post_title] => Novartis – MPP, Nilotinib, Non-Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novartis-mpp-nilotinib-non-exclusive-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2025-10-15 11:11:41
[post_modified_gmt] => 2025-10-15 11:11:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12016
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 12117
[post_author] => 5
[post_date] => 2024-10-17 09:08:28
[post_date_gmt] => 2024-10-17 09:08:28
[post_content] =>
[post_title] => Novartis – MPP, Nilotinib, Non-Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novartis-mpp-nilotinib-non-exclusive-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-17 09:08:28
[post_modified_gmt] => 2024-10-17 09:08:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12117
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 12126
[post_author] => 5
[post_date] => 2024-10-17 09:05:38
[post_date_gmt] => 2024-10-17 09:05:38
[post_content] =>
[post_title] => Novartis – MPP, Nilotinib, Non-Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novartis-mpp-nilotinib-non-exclusive-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-17 10:04:30
[post_modified_gmt] => 2024-10-17 10:04:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12126
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 12097
[post_author] => 5
[post_date] => 2024-10-09 14:59:36
[post_date_gmt] => 2024-10-09 14:59:36
[post_content] =>
[post_title] => MPP - Biovac, mRNA Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-biovac-mrna-vaccine-technology-transfer-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-09 14:59:36
[post_modified_gmt] => 2024-10-09 14:59:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12097
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 12040
[post_author] => 5
[post_date] => 2024-09-06 15:04:16
[post_date_gmt] => 2024-09-06 15:04:16
[post_content] =>
[post_title] => AbbVie – MPP, HIV Antiretroviral (lopinavir, ritonavir – LPV/r) Pediatric License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => abbvie-mpp-hiv-antiretroviral-lopinavir-ritonavir-lpv-r-pediatric-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-05 15:11:50
[post_modified_gmt] => 2024-11-05 15:11:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12040
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 12031
[post_author] => 5
[post_date] => 2024-09-05 10:50:42
[post_date_gmt] => 2024-09-05 10:50:42
[post_content] =>
[post_title] => BMS - MPP, Hepatitis C Antiviral (daclatasvir - DAC) License & Tech Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bms-mpp-hepatitis-c-antiviral-daclatasvir-dac-license-tech-transfer-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-05 12:58:28
[post_modified_gmt] => 2024-09-05 12:58:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12031
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 12026
[post_author] => 5
[post_date] => 2024-09-04 15:25:56
[post_date_gmt] => 2024-09-04 15:25:56
[post_content] =>
[post_title] => AbbVie – MPP, HIV Antiretroviral (lopinavir, ritonavir – LPV/r) Pediatric License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => abbvie-mpp-hiv-antiretroviral-lopinavir-ritonavir-lpv-r-pediatric-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-05 14:52:17
[post_modified_gmt] => 2024-11-05 14:52:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12026
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 12023
[post_author] => 5
[post_date] => 2024-09-04 13:09:05
[post_date_gmt] => 2024-09-04 13:09:05
[post_content] =>
[post_title] => AbbVie – MPP, HIV Antiretroviral (lopinavir, ritonavir - LPV/r) License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => abbvie-mpp-hiv-antiretroviral-lopinavir-ritonavir-lpv-r-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 13:09:05
[post_modified_gmt] => 2024-09-04 13:09:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12023
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 11816
[post_author] => 5
[post_date] => 2024-09-04 10:53:36
[post_date_gmt] => 2024-09-04 10:53:36
[post_content] =>
[post_title] => Pfizer - MPP, TB Therapeutic (Sutezolid) Non-Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-mpp-tb-therapeutic-sutezolid-non-exclusive-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:53:36
[post_modified_gmt] => 2024-09-04 10:53:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11816
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 11817
[post_author] => 5
[post_date] => 2024-09-04 10:53:13
[post_date_gmt] => 2024-09-04 10:53:13
[post_content] =>
[post_title] => MPP - Gates Medical Research Institute, TB therapeutic (Sutezolid) Sublicense Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-gates-medical-research-institute-tb-therapeutic-sutezolid-sublicense-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:53:13
[post_modified_gmt] => 2024-09-04 10:53:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11817
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 12019
[post_author] => 5
[post_date] => 2024-09-04 10:27:15
[post_date_gmt] => 2024-09-04 10:27:15
[post_content] =>
[post_title] => BMS - MPP, HIV Antiretroviral (atazanavir - ATV) License and Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bms-mpp-sublicense-tech-transfer-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-05 13:02:57
[post_modified_gmt] => 2024-09-05 13:02:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=12019
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 11809
[post_author] => 5
[post_date] => 2024-05-30 14:34:08
[post_date_gmt] => 2024-05-30 14:34:08
[post_content] =>
[post_title] => Pfizer - MPP, TB Therapeutic (Sutezolid) Non-Exclusive License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-mpp-tb-therapeutic-sutezolid-non-exclusive-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2024-05-31 07:05:35
[post_modified_gmt] => 2024-05-31 07:05:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11809
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 11794
[post_author] => 5
[post_date] => 2024-05-30 09:59:21
[post_date_gmt] => 2024-05-30 09:59:21
[post_content] =>
[post_title] => MPP – Gates Medical Research Institute, TB therapeutic (Sutezolid) Sublicense Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-gates-medical-research-institute-tb-therapeutic-sutezolid-sublicense-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-05-30 11:13:31
[post_modified_gmt] => 2024-05-30 11:13:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11794
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 11480
[post_author] => 5
[post_date] => 2023-11-20 09:24:22
[post_date_gmt] => 2023-11-20 09:24:22
[post_content] =>
[post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:51:14
[post_modified_gmt] => 2024-09-04 10:51:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11480
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 11471
[post_author] => 5
[post_date] => 2023-11-20 08:40:37
[post_date_gmt] => 2023-11-20 08:40:37
[post_content] =>
[post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-28 12:47:50
[post_modified_gmt] => 2024-10-28 12:47:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11471
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 11468
[post_author] => 5
[post_date] => 2023-11-20 08:37:54
[post_date_gmt] => 2023-11-20 08:37:54
[post_content] =>
[post_title] => GARDP – Orchid, Cefiderocol Manufacturing Sublicense and Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gardp-orchid-cefiderocol-manufacturing-sublicense-and-technology-transfer-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2023-11-20 09:25:50
[post_modified_gmt] => 2023-11-20 09:25:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11468
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 11356
[post_author] => 5
[post_date] => 2023-10-11 13:32:54
[post_date_gmt] => 2023-10-11 13:32:54
[post_content] =>
[post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:51:51
[post_modified_gmt] => 2024-09-04 10:51:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=11356
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 3910
[post_author] => 5
[post_date] => 2022-12-15 14:44:16
[post_date_gmt] => 2022-12-15 14:44:16
[post_content] =>
[post_title] => Merck – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:52:12
[post_modified_gmt] => 2024-09-04 10:52:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3910
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 8131
[post_author] => 5
[post_date] => 2022-12-12 09:57:36
[post_date_gmt] => 2022-12-12 09:57:36
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-18 15:13:14
[post_modified_gmt] => 2024-11-18 15:13:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 8130
[post_author] => 5
[post_date] => 2022-12-12 09:34:49
[post_date_gmt] => 2022-12-12 09:34:49
[post_content] =>
[post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-18 15:13:39
[post_modified_gmt] => 2024-11-18 15:13:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8130
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 8051
[post_author] => 5
[post_date] => 2022-12-12 08:39:19
[post_date_gmt] => 2022-12-12 08:39:19
[post_content] =>
[post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-11-18 15:14:21
[post_modified_gmt] => 2024-11-18 15:14:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=8051
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 7580
[post_author] => 5
[post_date] => 2022-12-08 08:14:21
[post_date_gmt] => 2022-12-08 08:14:21
[post_content] =>
[post_title] => FIND Sample Funding Terms and Conditions
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => find-sample-funding-terms-and-conditions-7
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:50:41
[post_modified_gmt] => 2024-09-04 10:50:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=7580
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 6636
[post_author] => 5
[post_date] => 2022-11-09 13:21:22
[post_date_gmt] => 2022-11-09 13:21:22
[post_content] =>
[post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-11 09:35:07
[post_modified_gmt] => 2023-07-11 09:35:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6636
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 6635
[post_author] => 5
[post_date] => 2022-11-09 13:05:41
[post_date_gmt] => 2022-11-09 13:05:41
[post_content] =>
[post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-19 15:11:40
[post_modified_gmt] => 2024-08-19 15:11:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6635
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 6634
[post_author] => 5
[post_date] => 2022-11-08 19:23:52
[post_date_gmt] => 2022-11-08 19:23:52
[post_content] =>
[post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-11 09:43:33
[post_modified_gmt] => 2023-07-11 09:43:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6634
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 6632
[post_author] => 5
[post_date] => 2022-11-08 18:14:54
[post_date_gmt] => 2022-11-08 18:14:54
[post_content] =>
[post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-11 08:47:59
[post_modified_gmt] => 2023-07-11 08:47:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6632
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[50] => WP_Post Object
(
[ID] => 6631
[post_author] => 5
[post_date] => 2022-11-08 16:07:28
[post_date_gmt] => 2022-11-08 16:07:28
[post_content] =>
[post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2025-08-20 08:59:54
[post_modified_gmt] => 2025-08-20 08:59:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6631
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[51] => WP_Post Object
(
[ID] => 6630
[post_author] => 5
[post_date] => 2022-11-08 15:22:11
[post_date_gmt] => 2022-11-08 15:22:11
[post_content] =>
[post_title] => Gates Foundation – Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-11 08:56:26
[post_modified_gmt] => 2023-07-11 08:56:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6630
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[52] => WP_Post Object
(
[ID] => 6628
[post_author] => 5
[post_date] => 2022-11-08 13:12:06
[post_date_gmt] => 2022-11-08 13:12:06
[post_content] =>
[post_title] => Gates Foundation - Novavax, RSV Vaccine Global Access Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-novavax-rsv-vaccine-global-access-commitments-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-19 15:13:38
[post_modified_gmt] => 2024-08-19 15:13:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=6628
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[53] => WP_Post Object
(
[ID] => 5800
[post_author] => 5
[post_date] => 2022-09-28 07:45:10
[post_date_gmt] => 2022-09-28 07:45:10
[post_content] =>
[post_title] => Gilead – MPP – Arene Lifesciences, HIV Therapeutic License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gilead-mpp-arene-lifesciences-hiv-therapeutic-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-19 14:46:23
[post_modified_gmt] => 2024-09-19 14:46:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[54] => WP_Post Object
(
[ID] => 5281
[post_author] => 5
[post_date] => 2022-07-08 12:00:54
[post_date_gmt] => 2022-07-08 12:00:54
[post_content] =>
[post_title] => Shionogi – GARDP, Cefiderocol License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => shionogi-gardp-cefiderocol-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:54:17
[post_modified_gmt] => 2024-09-04 10:54:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5281
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[55] => WP_Post Object
(
[ID] => 5278
[post_author] => 5
[post_date] => 2022-07-08 10:25:20
[post_date_gmt] => 2022-07-08 10:25:20
[post_content] =>
[post_title] => Shionogi – GARDP, Cefiderocol License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => shionogi-gardp-cefiderocol-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2023-07-18 11:50:51
[post_modified_gmt] => 2023-07-18 11:50:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5278
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[56] => WP_Post Object
(
[ID] => 5270
[post_author] => 5
[post_date] => 2022-07-08 08:12:42
[post_date_gmt] => 2022-07-08 08:12:42
[post_content] =>
[post_title] => Shionogi - GARDP, Cefiderocol License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => shionogi-gardp-cefiderocol-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2024-01-09 13:26:03
[post_modified_gmt] => 2024-01-09 13:26:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5270
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[57] => WP_Post Object
(
[ID] => 4161
[post_author] => 5
[post_date] => 2022-02-02 13:48:58
[post_date_gmt] => 2022-02-02 13:48:58
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-20 13:31:52
[post_modified_gmt] => 2024-08-20 13:31:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4161
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[58] => WP_Post Object
(
[ID] => 4089
[post_author] => 5
[post_date] => 2022-01-11 13:35:45
[post_date_gmt] => 2022-01-11 13:35:45
[post_content] =>
[post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-04 10:55:45
[post_modified_gmt] => 2024-09-04 10:55:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4089
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[59] => WP_Post Object
(
[ID] => 4077
[post_author] => 5
[post_date] => 2022-01-11 07:20:11
[post_date_gmt] => 2022-01-11 07:20:11
[post_content] =>
[post_title] => University of Washington – MPP, Long-acting Injectable HIV Treatment License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => university-of-washington-medicines-patent-pool-long-acting-injectable-hiv-treatment-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2023-11-10 15:02:23
[post_modified_gmt] => 2023-11-10 15:02:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4077
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[60] => WP_Post Object
(
[ID] => 3895
[post_author] => 5
[post_date] => 2021-11-22 10:20:20
[post_date_gmt] => 2021-11-22 10:20:20
[post_content] =>
[post_title] => Merck – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2024-09-20 08:33:01
[post_modified_gmt] => 2024-09-20 08:33:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3895
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[61] => WP_Post Object
(
[ID] => 3892
[post_author] => 5
[post_date] => 2021-11-19 13:53:26
[post_date_gmt] => 2021-11-19 13:53:26
[post_content] =>
[post_title] => Merck – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2025-09-18 14:49:01
[post_modified_gmt] => 2025-09-18 14:49:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[62] => WP_Post Object
(
[ID] => 2889
[post_author] => 6
[post_date] => 2021-05-14 19:09:07
[post_date_gmt] => 2021-05-14 19:09:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2024-10-21 11:28:56
[post_modified_gmt] => 2024-10-21 11:28:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2889
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[invalid_get] =>
[is_text_search] =>
[has_agreement_filters] =>
[has_any_agreement_filter] => Array
(
)
[found_agreements] =>
[has_provision_filters] => 1
[found_provisions] => 1
[lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
[lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
[lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
[lbl_agreement_type:GHIAA2019\MapguideSearch:private] => Agreement Type:
[lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
[lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
[lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
[issues_by_id:GHIAA2019\MapguideSearch:private] => Array
(
[101] => WP_Term Object
(
[term_id] => 101
[name] => Access plans & principles
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
How should equitable or global access be defined?
Should the developer be required to comply with an equitable access policy?
Should the developer be required to establish an access plan?
[parent] => 46
[count] => 64
[filter] => raw
[parent_name] => Equitable access
[parent_slug] => access-to-medicines
)
[100] => WP_Term Object
(
[term_id] => 100
[name] => Affordable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 57
[filter] => raw
[parent_name] => Equitable access
[parent_slug] => access-to-medicines
)
[66] => WP_Term Object
(
[term_id] => 66
[name] => Benefit sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 19
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[53] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[371] => WP_Term Object
(
[term_id] => 371
[name] => Clinical trial conduct
[slug] => clinical-trial-conduct
[term_group] => 0
[term_taxonomy_id] => 371
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 16
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[84] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
What is the scope of confidential information?
What are the obligations of the parties to protect confidential information?
Are there any exceptions to the confidentiality obligations?
Are the parties permitted to make public announcements related to the project?
Can the parties use each other’s name and logo for general marketing materials?
[parent] => 49
[count] => 123
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[271] => WP_Term Object
(
[term_id] => 271
[name] => Donation
[slug] => donation
[term_group] => 0
[term_taxonomy_id] => 271
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Equitable access
[parent_slug] => access-to-medicines
)
[72] => WP_Term Object
(
[term_id] => 72
[name] => Effects of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 106
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[281] => WP_Term Object
(
[term_id] => 281
[name] => Ensuring continuity
[slug] => ensuring-continuity
[term_group] => 0
[term_taxonomy_id] => 281
[taxonomy] => issue
[description] =>
Under what circumstances can the continuity rights be exercised? (What are the conditions precedent?)
What is an appropriate scope for the continuity rights? What are the rights and obligations of each party?
Should related license grants vest upon execution of the agreement, or at a later stage in development?
Should there be an escrow requirement?
Should there be any restrictions on the developer’s ability to transfer project-related intellectual property to a third party?
[parent] => 46
[count] => 64
[filter] => raw
[parent_name] => Equitable access
[parent_slug] => access-to-medicines
)
[46] => WP_Term Object
(
[term_id] => 46
[name] => Equitable access
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[278] => WP_Term Object
(
[term_id] => 278
[name] => Governance
[slug] => roles-responsibilities
[term_group] => 0
[term_taxonomy_id] => 278
[taxonomy] => issue
[description] =>
Do the parties govern the project through a joint steering committee ("JSC")? If so, what are the parties expressly designated roles and responsibilities with respect to the JSC?
Are there other committees, important governance bodies, or designated individual positions? What are the parties' roles and responsibilities with respect to them?
Are the parties required to meet in accordance with a defined schedule for decision-making and progress reporting activities?
What are the resolution mechanisms for disputes related to the agreement?
Are there any requirements for policies or procedures to manage potential conflicts of interest?
[parent] => 53
[count] => 109
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[80] => WP_Term Object
(
[term_id] => 80
[name] => Indemnification & liability
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
What occurrences could result in a liability claim against which one party will indemnify the other?
Are there any circumstances under which one party will not indemnify the other?
What is the process for managing liability claims?
Are there government or other types of indemnification schemes?
Is there any limitation or monetary cap on each party’s liabilities under the agreement?
[parent] => 50
[count] => 120
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[257] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
What financial and project progress information must be shared between the parties?
What is the required timeline for sharing information?
How is the receiving party permitted to use the information received?
Do the parties have the right to verify the information reported?
[parent] => 49
[count] => 114
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[109] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 76
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[48] => WP_Term Object
(
[term_id] => 48
[name] => Intellectual property
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[50] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[88] => WP_Term Object
(
[term_id] => 88
[name] => License grants
[slug] => license-grants
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
Are any licenses granted for the use of background or foreground intellectual property?
What is the scope of the licensed intellectual property?
What is the territory of the license?
Is the license exclusive or non-exclusive?
Are there any restrictions on the use of the licensed intellectual property?
Are there any specific obligations to exploit the licensed intellectual property?
Can the licensee grant sublicenses to third parties?
Will products manufactured under license be marketed as branded or generic? (i.e. will they bear the licensor’s trademarks/trade dress)
[parent] => 48
[count] => 115
[filter] => raw
[parent_name] => Intellectual property
[parent_slug] => ip-ownership
)
[87] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of IP
[slug] => ownership-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 87
[filter] => raw
[parent_name] => Intellectual property
[parent_slug] => ip-ownership
)
[70] => WP_Term Object
(
[term_id] => 70
[name] => Payment structures
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] => What is the payment structure under this agreement?
What are the mechanisms to limit exposure to additional payments or expenses?
[parent] => 53
[count] => 98
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[102] => WP_Term Object
(
[term_id] => 102
[name] => Preparedness & response
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 16
[filter] => raw
[parent_name] => Equitable access
[parent_slug] => access-to-medicines
)
[268] => WP_Term Object
(
[term_id] => 268
[name] => Product supply
[slug] => supply-purchase-of-products
[term_group] => 0
[term_taxonomy_id] => 268
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 47
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[49] => WP_Term Object
(
[term_id] => 49
[name] => Protecting & sharing information
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[90] => WP_Term Object
(
[term_id] => 90
[name] => Protection of IP
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 91
[filter] => raw
[parent_name] => Intellectual property
[parent_slug] => ip-ownership
)
[290] => WP_Term Object
(
[term_id] => 290
[name] => Publication of results
[slug] => publication-of-results
[term_group] => 0
[term_taxonomy_id] => 290
[taxonomy] => issue
[description] => What information are the parties required or permitted to publish?
What is the required timeline for making data available?
What are the acceptable publication channels?
Is compliance with a specific open access policy required?
[parent] => 49
[count] => 72
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[372] => WP_Term Object
(
[term_id] => 372
[name] => Quality management
[slug] => quality-management
[term_group] => 0
[term_taxonomy_id] => 372
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 47
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[56] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 62
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[81] => WP_Term Object
(
[term_id] => 81
[name] => Representations & warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] => Should the parties make any warranties, and if so, what is the scope?
[parent] => 50
[count] => 108
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[86] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] => What is included in the technology and/or materials to be transferred?
What are the responsibilities of each party to in relation to the transfer of materials and/or technology?
[parent] => 49
[count] => 49
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[52] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] => Term
What is the term of the agreement? Is it tied to the timeline of the project or license grants?
Termination
Under what circumstances may a party terminate or withdraw from the agreement?
Effects of Termination
What are the effects of termination or withdrawal by a party?
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[76] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 107
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[74] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 112
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[282] => WP_Term Object
(
[term_id] => 282
[name] => Territory access commitments
[slug] => territory-access-commitments
[term_group] => 0
[term_taxonomy_id] => 282
[taxonomy] => issue
[description] =>
How should ‘territory’ be defined under the agreement? Should the definition make a distinction between different types of purchaser (e.g. public sector vs. private sector)?
Should the developer be required to apply for regulatory approval in priority access markets?
Should the developer be required to commit a proportion of the product manufactured to a certain country or purchasing organization?
Should the developer be required to identify a third party that could fulfill supply requirements for the access territories in the event that the developer does not?
Should the agreement include any anti-diversion provisions?
[parent] => 46
[count] => 69
[filter] => raw
[parent_name] => Equitable access
[parent_slug] => access-to-medicines
)
)
[issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
(
[equitable-access] => WP_Term Object
(
[term_id] => 101
[name] => Access plans & principles
[slug] => equitable-access
[term_group] => 0
[term_taxonomy_id] => 101
[taxonomy] => issue
[description] =>
How should equitable or global access be defined?
Should the developer be required to comply with an equitable access policy?
Should the developer be required to establish an access plan?
[parent] => 46
[count] => 64
[filter] => raw
[parent_name] => Equitable access
[parent_slug] => access-to-medicines
)
[pricing] => WP_Term Object
(
[term_id] => 100
[name] => Affordable pricing
[slug] => pricing
[term_group] => 0
[term_taxonomy_id] => 100
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 57
[filter] => raw
[parent_name] => Equitable access
[parent_slug] => access-to-medicines
)
[benefit-revenue-sharing] => WP_Term Object
(
[term_id] => 66
[name] => Benefit sharing
[slug] => benefit-revenue-sharing
[term_group] => 0
[term_taxonomy_id] => 66
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 19
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[business-model] => WP_Term Object
(
[term_id] => 53
[name] => Business model
[slug] => business-model
[term_group] => 0
[term_taxonomy_id] => 53
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[clinical-trial-conduct] => WP_Term Object
(
[term_id] => 371
[name] => Clinical trial conduct
[slug] => clinical-trial-conduct
[term_group] => 0
[term_taxonomy_id] => 371
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 16
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[confidentiality] => WP_Term Object
(
[term_id] => 84
[name] => Confidentiality
[slug] => confidentiality
[term_group] => 0
[term_taxonomy_id] => 84
[taxonomy] => issue
[description] =>
What is the scope of confidential information?
What are the obligations of the parties to protect confidential information?
Are there any exceptions to the confidentiality obligations?
Are the parties permitted to make public announcements related to the project?
Can the parties use each other’s name and logo for general marketing materials?
[parent] => 49
[count] => 123
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[donation] => WP_Term Object
(
[term_id] => 271
[name] => Donation
[slug] => donation
[term_group] => 0
[term_taxonomy_id] => 271
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 5
[filter] => raw
[parent_name] => Equitable access
[parent_slug] => access-to-medicines
)
[effect-of-termination] => WP_Term Object
(
[term_id] => 72
[name] => Effects of termination
[slug] => effect-of-termination
[term_group] => 0
[term_taxonomy_id] => 72
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 106
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[ensuring-continuity] => WP_Term Object
(
[term_id] => 281
[name] => Ensuring continuity
[slug] => ensuring-continuity
[term_group] => 0
[term_taxonomy_id] => 281
[taxonomy] => issue
[description] =>
Under what circumstances can the continuity rights be exercised? (What are the conditions precedent?)
What is an appropriate scope for the continuity rights? What are the rights and obligations of each party?
Should related license grants vest upon execution of the agreement, or at a later stage in development?
Should there be an escrow requirement?
Should there be any restrictions on the developer’s ability to transfer project-related intellectual property to a third party?
[parent] => 46
[count] => 64
[filter] => raw
[parent_name] => Equitable access
[parent_slug] => access-to-medicines
)
[access-to-medicines] => WP_Term Object
(
[term_id] => 46
[name] => Equitable access
[slug] => access-to-medicines
[term_group] => 0
[term_taxonomy_id] => 46
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[roles-responsibilities] => WP_Term Object
(
[term_id] => 278
[name] => Governance
[slug] => roles-responsibilities
[term_group] => 0
[term_taxonomy_id] => 278
[taxonomy] => issue
[description] =>
Do the parties govern the project through a joint steering committee ("JSC")? If so, what are the parties expressly designated roles and responsibilities with respect to the JSC?
Are there other committees, important governance bodies, or designated individual positions? What are the parties' roles and responsibilities with respect to them?
Are the parties required to meet in accordance with a defined schedule for decision-making and progress reporting activities?
What are the resolution mechanisms for disputes related to the agreement?
Are there any requirements for policies or procedures to manage potential conflicts of interest?
[parent] => 53
[count] => 109
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[indemnity] => WP_Term Object
(
[term_id] => 80
[name] => Indemnification & liability
[slug] => indemnity
[term_group] => 0
[term_taxonomy_id] => 80
[taxonomy] => issue
[description] =>
What occurrences could result in a liability claim against which one party will indemnify the other?
Are there any circumstances under which one party will not indemnify the other?
What is the process for managing liability claims?
Are there government or other types of indemnification schemes?
Is there any limitation or monetary cap on each party’s liabilities under the agreement?
[parent] => 50
[count] => 120
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[information-sharing-information-sharing] => WP_Term Object
(
[term_id] => 257
[name] => Information sharing
[slug] => information-sharing-information-sharing
[term_group] => 0
[term_taxonomy_id] => 257
[taxonomy] => issue
[description] =>
What financial and project progress information must be shared between the parties?
What is the required timeline for sharing information?
How is the receiving party permitted to use the information received?
Do the parties have the right to verify the information reported?
[parent] => 49
[count] => 114
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[insurance] => WP_Term Object
(
[term_id] => 109
[name] => Insurance
[slug] => insurance
[term_group] => 0
[term_taxonomy_id] => 109
[taxonomy] => issue
[description] =>
[parent] => 50
[count] => 76
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[ip-ownership] => WP_Term Object
(
[term_id] => 48
[name] => Intellectual property
[slug] => ip-ownership
[term_group] => 0
[term_taxonomy_id] => 48
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[liability] => WP_Term Object
(
[term_id] => 50
[name] => Liability
[slug] => liability
[term_group] => 0
[term_taxonomy_id] => 50
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[license-grants] => WP_Term Object
(
[term_id] => 88
[name] => License grants
[slug] => license-grants
[term_group] => 0
[term_taxonomy_id] => 88
[taxonomy] => issue
[description] =>
Are any licenses granted for the use of background or foreground intellectual property?
What is the scope of the licensed intellectual property?
What is the territory of the license?
Is the license exclusive or non-exclusive?
Are there any restrictions on the use of the licensed intellectual property?
Are there any specific obligations to exploit the licensed intellectual property?
Can the licensee grant sublicenses to third parties?
Will products manufactured under license be marketed as branded or generic? (i.e. will they bear the licensor’s trademarks/trade dress)
[parent] => 48
[count] => 115
[filter] => raw
[parent_name] => Intellectual property
[parent_slug] => ip-ownership
)
[ownership-ip] => WP_Term Object
(
[term_id] => 87
[name] => Ownership of IP
[slug] => ownership-ip
[term_group] => 0
[term_taxonomy_id] => 87
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 87
[filter] => raw
[parent_name] => Intellectual property
[parent_slug] => ip-ownership
)
[royalties-and-payments] => WP_Term Object
(
[term_id] => 70
[name] => Payment structures
[slug] => royalties-and-payments
[term_group] => 0
[term_taxonomy_id] => 70
[taxonomy] => issue
[description] => What is the payment structure under this agreement?
What are the mechanisms to limit exposure to additional payments or expenses?
[parent] => 53
[count] => 98
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[outbreak-preparedness] => WP_Term Object
(
[term_id] => 102
[name] => Preparedness & response
[slug] => outbreak-preparedness
[term_group] => 0
[term_taxonomy_id] => 102
[taxonomy] => issue
[description] =>
[parent] => 46
[count] => 16
[filter] => raw
[parent_name] => Equitable access
[parent_slug] => access-to-medicines
)
[supply-purchase-of-products] => WP_Term Object
(
[term_id] => 268
[name] => Product supply
[slug] => supply-purchase-of-products
[term_group] => 0
[term_taxonomy_id] => 268
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 47
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[information-sharing] => WP_Term Object
(
[term_id] => 49
[name] => Protecting & sharing information
[slug] => information-sharing
[term_group] => 0
[term_taxonomy_id] => 49
[taxonomy] => issue
[description] =>
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[protection-results] => WP_Term Object
(
[term_id] => 90
[name] => Protection of IP
[slug] => protection-results
[term_group] => 0
[term_taxonomy_id] => 90
[taxonomy] => issue
[description] =>
[parent] => 48
[count] => 91
[filter] => raw
[parent_name] => Intellectual property
[parent_slug] => ip-ownership
)
[publication-of-results] => WP_Term Object
(
[term_id] => 290
[name] => Publication of results
[slug] => publication-of-results
[term_group] => 0
[term_taxonomy_id] => 290
[taxonomy] => issue
[description] => What information are the parties required or permitted to publish?
What is the required timeline for making data available?
What are the acceptable publication channels?
Is compliance with a specific open access policy required?
[parent] => 49
[count] => 72
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[quality-management] => WP_Term Object
(
[term_id] => 372
[name] => Quality management
[slug] => quality-management
[term_group] => 0
[term_taxonomy_id] => 372
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 47
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[regulatory-strategy] => WP_Term Object
(
[term_id] => 56
[name] => Regulatory strategy
[slug] => regulatory-strategy
[term_group] => 0
[term_taxonomy_id] => 56
[taxonomy] => issue
[description] =>
[parent] => 53
[count] => 62
[filter] => raw
[parent_name] => Business model
[parent_slug] => business-model
)
[warranties] => WP_Term Object
(
[term_id] => 81
[name] => Representations & warranties
[slug] => warranties
[term_group] => 0
[term_taxonomy_id] => 81
[taxonomy] => issue
[description] => Should the parties make any warranties, and if so, what is the scope?
[parent] => 50
[count] => 108
[filter] => raw
[parent_name] => Liability
[parent_slug] => liability
)
[technology-transfer] => WP_Term Object
(
[term_id] => 86
[name] => Technology transfer
[slug] => technology-transfer
[term_group] => 0
[term_taxonomy_id] => 86
[taxonomy] => issue
[description] => What is included in the technology and/or materials to be transferred?
What are the responsibilities of each party to in relation to the transfer of materials and/or technology?
[parent] => 49
[count] => 49
[filter] => raw
[parent_name] => Protecting & sharing information
[parent_slug] => information-sharing
)
[term-and-termination] => WP_Term Object
(
[term_id] => 52
[name] => Term & termination
[slug] => term-and-termination
[term_group] => 0
[term_taxonomy_id] => 52
[taxonomy] => issue
[description] => Term
What is the term of the agreement? Is it tied to the timeline of the project or license grants?
Termination
Under what circumstances may a party terminate or withdraw from the agreement?
Effects of Termination
What are the effects of termination or withdrawal by a party?
[parent] => 0
[count] => 0
[filter] => raw
[parent_name] =>
[parent_slug] =>
)
[term-of-agreement] => WP_Term Object
(
[term_id] => 76
[name] => Term of agreement
[slug] => term-of-agreement
[term_group] => 0
[term_taxonomy_id] => 76
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 107
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[termination-and-withdrawal] => WP_Term Object
(
[term_id] => 74
[name] => Termination & withdrawal
[slug] => termination-and-withdrawal
[term_group] => 0
[term_taxonomy_id] => 74
[taxonomy] => issue
[description] =>
[parent] => 52
[count] => 112
[filter] => raw
[parent_name] => Term & termination
[parent_slug] => term-and-termination
)
[territory-access-commitments] => WP_Term Object
(
[term_id] => 282
[name] => Territory access commitments
[slug] => territory-access-commitments
[term_group] => 0
[term_taxonomy_id] => 282
[taxonomy] => issue
[description] =>
How should ‘territory’ be defined under the agreement? Should the definition make a distinction between different types of purchaser (e.g. public sector vs. private sector)?
Should the developer be required to apply for regulatory approval in priority access markets?
Should the developer be required to commit a proportion of the product manufactured to a certain country or purchasing organization?
Should the developer be required to identify a third party that could fulfill supply requirements for the access territories in the event that the developer does not?
Should the agreement include any anti-diversion provisions?
[parent] => 46
[count] => 69
[filter] => raw
[parent_name] => Equitable access
[parent_slug] => access-to-medicines
)
)
[filter_issues:GHIAA2019\MapguideSearch:private] => Array
(
)
)